It is known that GH/IGF-I hypersecretion provides anabolic and lipolytic effects, while the most common lipid profile alterations are hypertriglyceridemia (occurring in 33–40% of patients with acromegaly, which is three times higher than in the general population) and low levels of HDL cholesterol (39–47% of cases), whereas the prevalence of hypercholesterolemia is similar to that of the general population (3). This evidence concerns the gene IGF1 and acromegaly.